London
8 °C
Manchester
6 °C
Glasgow
Dublin
Belfast
Washington
3 °C
Denver
9 °C
Atlanta
Dallas
Houston Texas
17 °C
New Orleans
El Paso
Phoenix
Los Angeles
-20 °C
28 °C
14 °C
Moderna announces positive results for Omicron vaccine / Photo: © AFP
NYSE - LSE
| SCS | 0.12% | 16.14 | $ | |
| RYCEF | -2.1% | 16.65 | $ | |
| CMSC | -0.51% | 23.54 | $ | |
| RBGPF | 0.12% | 82.5 | $ | |
| RELX | -1.65% | 30.015 | $ | |
| CMSD | -0.5% | 23.82 | $ | |
| NGG | 2.37% | 88.32 | $ | |
| RIO | -0.47% | 95.92 | $ | |
| GSK | 7.05% | 57.383 | $ | |
| BCE | 1.12% | 26.395 | $ | |
| VOD | 2.97% | 15.717 | $ | |
| BCC | 5.5% | 89.87 | $ | |
| AZN | 1.98% | 188.04 | $ | |
| BTI | -0.21% | 61.74 | $ | |
| JRI | 0.04% | 13.125 | $ | |
| BP | 1.51% | 39.415 | $ |
Moderna announces positive results for Omicron vaccine
US biotech company Moderna on Wednesday announced positive results for a new vaccine that targets both the original Covid strain and Omicron.
This so-called "bivalent" vaccine was tested in a trial of more 850 adults, who had all received their first three doses of Moderna's original Spikevax vaccine.
Around half the group then received a fourth dose of Spikevax, while the rest received the bivalent vaccine.
Those who received the bivalent vaccine had significantly higher levels of neutralizing antibodies -- Y-shaped immune system proteins that block the virus -- against Omicron.
On average, these levels were around 75 percent higher in the group who got the bivalent vaccine as a fourth dose compared to those who got the original vaccine as a fourth dose. They also received slightly superior protection to the ancestral strain of Covid compared to Spikevax.
"We are thrilled," said Stephane Bancel, CEO of Moderna in a statement, adding he anticipated this vaccine would be the company's lead candidate for authorization as a booster this fall.
"We want to be as ready as early as August for shipping," he told investors in a call.
Stephen Hoge, the company's president, did concede that antibody levels would be lower against Omicron's sub variants that are now in circulation, but said he believed it was still a superior booster than repeating Spikevax.
The company doesn't yet have data on durability -- how the new vaccine booster will fare three months and six months out.
A panel of Food and Drug Administration experts will meet June 28 to discuss considerations and strategies for boosters in fall and winter.
C.Diaz--SFF
